Góralska Joanna, Śliwa Agnieszka, Gruca Anna, Raźny Urszula, Chojnacka Monika, Polus Anna, Solnica Bogdan, Malczewska-Malec Małgorzata
Department of Clinical Biochemistry, Medical College, Jagiellonian University, Kraków, Poland.
Acta Biochim Pol. 2017;64(3):423-429. doi: 10.18388/abp.2017_1634. Epub 2017 Aug 19.
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are relatively new pharmacological agents used to normalize glucose level in type 2 diabetes. Recently, GLP-1RAs have been approved for the treatment of obesity to reduce body weight in non-diabetic patients. The extra-pancre-atic effects of GLP-1RAs, as well as their molecular mechanism of action, are still poorly understood. Thus this study was aimed to verify the hypothesis that the mechanism of action of the GLP-1RAs involves mitochondria and that GLP-1RAs administration can improve mitochondrial functions. For this purpose, preadipocytes CHUBS7 were differentiated to mature adipocytes and then stimulated with GLP-1RA, exendin-4 at 100 nM for 24 h. Oxygen consumption rates, mitochondrial membrane potential, intracellular ATP (adenosine triphosphate) level, SIRT1 and SIRT3 gene expression and the histone deacetylases' activity were measured. Exendin-4 was found to uncouple mitochondrial electron transport from ATP synthesis, slightly decreasing mitochondrial membrane potential in mature adipocytes. Routine respiration and uncoupled oxy- gen consumption rates were higher in exendin-4 treated adipocytes than in the non-treated cells. The ATP level remained unchanged. Exendin-4 enhanced SIRT1 and SIRT3 genes expression. Histone deacetylases' activity in the nuclear fraction was not affected by exendin-4, although the activity of class III histone deacetylases was increased. All of the effects on mitochondrial bioenergetics induced by exendin-4 were abolished by addition of glucagon-like peptide 1 receptor antagonist. In conclusion, exendin-4 activates the sirtuin pathway and increases energy expenditure in human adipocytes. Our results suggest another mechanism that may be responsible for body weight reduction observed in patients using GLP-1RAs.
胰高血糖素样肽1受体激动剂(GLP - 1RAs)是用于使2型糖尿病患者血糖水平正常化的相对较新的药物。最近,GLP - 1RAs已被批准用于治疗肥胖症,以减轻非糖尿病患者的体重。GLP - 1RAs的胰腺外作用及其分子作用机制仍知之甚少。因此,本研究旨在验证以下假设:GLP - 1RAs的作用机制涉及线粒体,并且给予GLP - 1RAs可以改善线粒体功能。为此,将前脂肪细胞CHUBS7分化为成熟脂肪细胞,然后用100 nM的GLP - 1RA艾塞那肽 - 4刺激24小时。测量了氧消耗率、线粒体膜电位、细胞内ATP(三磷酸腺苷)水平、SIRT1和SIRT3基因表达以及组蛋白脱乙酰酶的活性。发现艾塞那肽 - 4使线粒体电子传递与ATP合成解偶联,略微降低成熟脂肪细胞中的线粒体膜电位。在艾塞那肽 - 4处理的脂肪细胞中,常规呼吸和非偶联氧消耗率高于未处理的细胞。ATP水平保持不变。艾塞那肽 - 4增强了SIRT1和SIRT3基因的表达。尽管III类组蛋白脱乙酰酶的活性增加,但核部分中的组蛋白脱乙酰酶活性不受艾塞那肽 - 4的影响。添加胰高血糖素样肽1受体拮抗剂可消除艾塞那肽 - 4对线粒体生物能量学的所有影响。总之,艾塞那肽 - 4激活了去乙酰化酶途径并增加了人类脂肪细胞的能量消耗。我们的结果提示了另一种机制,可能是使用GLP - 1RAs的患者体重减轻的原因。